November 14, 2020 10:35 AM ESTUpdated November 16, 08:06 AM

Cytokinetics cheers a PhIII readout for their heart drug developed with Amgen, but analysts and investors aren't joining the party

Nicole DeFeudis

Editor

Fifteen years after it entered the clinic, Amgen $AMGN and Cytokinetics’ closely watched heart drug popped out the other side, meeting the primary endpoint in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Cytokinetics cheers a PhIII readout for their heart drug developed with Amgen, but analysts and investors aren't joining the party

Nicole DeFeudis

Editor

Sign up to read this article for free.

Novo Nordisk partners with Broad Institute spinout Photys after the startup's layoffs

Exclusive: Insitro makes headway on the harder road, discovering new ALS drug target

SiteOne Therapeutics, a pain biotech that's partnered with Vertex, nabs $100M

Aurion’s eye cell therapy improves vision in small study, plots Phase 3 trial

In surprise move, FDA's No. 2 Bumpus to leave agency at end of 2024

Major PBM reforms feature in Congress' year-end spending bill

Cy­to­ki­net­ics cheers a PhI­II read­out for their heart drug de­vel­oped with Am­gen, but an­a­lysts and in­vestors aren't join­ing the par­ty

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Au­ri­on’s eye cell ther­a­py im­proves vi­sion in small study, plots Phase 3 tri­al

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

Cytokinetics cheers a PhIII readout for their heart drug developed with Amgen, but analysts and investors aren't joining the party

Novo Nordisk partners with Broad Institute spinout Photys after the startup's layoffs

Exclusive: Insitro makes headway on the harder road, discovering new ALS drug target

SiteOne Therapeutics, a pain biotech that's partnered with Vertex, nabs $100M

Aurion’s eye cell therapy improves vision in small study, plots Phase 3 trial

In surprise move, FDA's No. 2 Bumpus to leave agency at end of 2024

Major PBM reforms feature in Congress' year-end spending bill